Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Detectable ctDNA after neoadjuvant chemotherapy was associated with the  recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

Fruquintinib Plus TAS-102 Demonstrates Efficacy and Acceptable Toxicity in Pretreated mCRC

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.

FDA Approves Trastuzumab Deruxtecan for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

News Network

ASH 2023 Study Highlights on the Real-World Impact of Liso-Cel in R/R Large B-Cell Lymphoma

ASH 2023 Study Highlights on the Real-World Impact of Liso-Cel in R/R Large B-Cell Lymphoma

Latest Conference Coverage